{"product_id":"henrui-business-model-canvas","title":"Jiangsu Hengrui Medicine Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas: strategic playbook for a leading pharmaceutical innovator\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Jiangsu Hengrui Medicine’s strategic playbook with a concise Business Model Canvas that maps its value propositions, key partners, and revenue engines. This snapshot highlights growth levers and competitive advantages—perfect for investors and strategists. Download the full, editable Canvas to unlock detailed insights and templates for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal pharma alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui leverages global pharma alliances for co-development and co-commercialization to expand reach and de-risk late-stage assets, tapping partners' market access, regulatory expertise and complementary portfolios. Structured upfronts and milestones often exceed $100m with royalties typically 2–15%, aligning incentives. Joint steering committees speed decision-making and execution across territories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic \u0026amp; hospital research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUniversity labs and leading hospitals supply cutting-edge science and patient recruitment for Jiangsu Hengrui Medicine, underpinning over 200 active clinical trials; access to KOLs improves trial design and endpoints. Real-world evidence partnerships validate outcomes post-launch across China’s hospital networks. Long-term MOUs secure pipeline flow, supporting sustained R\u0026amp;D; Hengrui reported R\u0026amp;D spend of about RMB 8.6 billion in 2023 (latest published).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs and CDMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExternalizing clinical and manufacturing capacity with CROs and CDMOs accelerates Hengrui timelines and adds flexibility, reducing fixed capital needs and enabling faster patient recruitment across regions. CROs now manage over 70% of clinical trial operations globally, ensuring multicenter coordination and data integrity at scale. CDMOs provide specialized biologics and sterile-injectable expertise, and robust quality agreements secure GMP compliance and supply continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulators \u0026amp; HTA bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly scientific advice from NMPA, FDA and EMA reduces approval risk and accelerates clinical development planning; proactive HTA engagement shapes pricing and reimbursement dossiers; cooperative safety-signal sharing strengthens pharmacovigilance credibility; policy dialogues enable clearer access pathways for Hengrui's oncology and innovative biologics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory alignment: early advice\u003c\/li\u003e\n\u003cli\u003eHTA impact: reimbursement dossiers\u003c\/li\u003e\n\u003cli\u003eSafety: joint pharmacovigilance\u003c\/li\u003e\n\u003cli\u003ePolicy: access pathway engagement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors \u0026amp; GPOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpnational and regional distributors secure hospital coverage cold-chain integrity for jiangsu hengrui supporting nationwide reach temperature-controlled logistics.\u003e\n\u003cpgpo partnerships drive tender wins and formulary placement with centralized procurement dynamics in china cutting unit drug costs boosting volume access\u003e\n\u003cpjoint demand planning and data-sharing with partners reduce stockouts returns while improving forecast accuracy service levels.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDistribution network: national + regional cold-chain coverage\u003c\/li\u003e\n\u003cli\u003eGPO impact: tender wins and formulary access\u003c\/li\u003e\n\u003cli\u003eOperational gains: fewer stockouts via joint planning\u003c\/li\u003e\n\u003cli\u003eAnalytics: data-sharing improves forecast accuracy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pjoint\u003e\u003c\/pgpo\u003e\u003c\/pnational\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-development de-risks late-stage assets — \u003cstrong\u003e\u0026gt;$100m\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHengrui leverages global pharma co-development and licensing to de-risk late-stage assets and access markets, with deal upfronts\/milestones often \u0026gt;$100m and royalties 2–15%. University and hospital partnerships feed 200+ active trials and KOL support; R\u0026amp;D spend was RMB 8.6bn in 2023, with CROs handling \u0026gt;70% of trial operations by 2024. National distributors and GPOs secure cold-chain hospital coverage and drive tender access in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive clinical trials\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2023)\u003c\/td\u003e\n\u003ctd\u003eRMB 8.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO-managed ops (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeal upfronts\/milestones\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$100m typical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA complete Business Model Canvas for Jiangsu Hengrui Medicine outlining nine blocks—customer segments (hospitals, distributors, patients), channels (hospital procurement, tenders, partnerships), value proposition (R\u0026amp;D-led oncology and specialty drugs), revenue streams, cost structure, key resources and activities, partners, and customer relations—highlighting competitive advantages, pipeline-driven growth and linked SWOT insights for investor and strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Jiangsu Hengrui Medicine’s business model with editable cells, relieving the pain of fragmented strategy by consolidating R\u0026amp;D, manufacturing, distribution and regulatory pathways into one clear, shareable snapshot for faster decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative drug R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiscovery, lead optimization and preclinical validation form Hengrui's pipeline engine, advancing candidates from hit to IND-ready compounds across oncology, cardiovascular, metabolic and immunology programs; oncology represents about 40% of the global clinical pipeline in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhase I–III trials across China and international sites establish safety and efficacy for Jiangsu Hengrui Medicine. Adaptive designs and seamless phase strategies compress timelines and reduce patient exposure. Global standards enable regulatory submissions to NMPA, FDA and EMA. Patient-centric protocols improve retention and data quality in multicenter studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGMP manufacturing at Jiangsu Hengrui scales up small molecules, biologics and injectables to secure supply, supporting multi-site output and clinical-to-commercial batches; in 2024 the group maintained R\u0026amp;D investment of RMB 7.9 billion to feed pipelines. Process validation and continuous improvement cut batch failures and lower unit cost, while tech transfer from R\u0026amp;D to plants reduces variability across sites. Digital MES and QMS deployments improved oversight and traceability, aligning plant KPIs with regulatory standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePreparation of CTAs, NDAs and MAAs enables approvals and market entry; pricing, tendering and reimbursement strategy secure uptake within China where basic medical insurance covers over 95% of the population (2024). HEOR and budget impact models drive payer adoption; label expansions extend asset lifecycles and maximize commercial value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCTAs\/NDAs\/MAAs: regulatory approvals\u003c\/li\u003e\n\u003cli\u003ePricing\/tendering: reimbursement access\u003c\/li\u003e\n\u003cli\u003eHEOR\/BIA: payer decisions\u003c\/li\u003e\n\u003cli\u003eLabel expansion: lifecycle management\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical \u0026amp; commercial execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedical Science Liaisons drive clinician education and evidence adoption, supporting Hengrui’s clinical commercialisation with over 2,000 peer-to-peer engagements in 2024.\u003c\/p\u003e\n\u003cp\u003eOmnichannel promotion—digital detailing, webinars and KOL partnerships—raised HCP awareness across China, contributing to national sales growth in 2024.\u003c\/p\u003e\n\u003cp\u003ePharmacovigilance and risk management maintained market access and safety reporting compliance; key account management aligned product rollout with hospital procurement priorities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMSL engagements: 2,000+ in 2024\u003c\/li\u003e\n\u003cli\u003eOmnichannel reach: digital + KOL integrated campaigns\u003c\/li\u003e\n\u003cli\u003eSafety: strengthened PV and RMP processes\u003c\/li\u003e\n\u003cli\u003eKey accounts: hospital-aligned formulary strategies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscovery to IND and Phase I-III trials plus GMP scale-up drive oncology-focused pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiscovery to IND, Phase I–III trials and GMP scale-up drive Hengrui’s pipeline (oncology ~40% of clinical assets in 2024). R\u0026amp;D spend was RMB 7.9 billion in 2024; MSLs delivered 2,000+ engagements. Regulatory filings, HEOR and PV secure market access and reimbursement across China (basic medical insurance covers \u0026gt;95% in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 7.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology share\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSL engagements\u003c\/td\u003e\n\u003ctd\u003e2,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you’re previewing is the actual Jiangsu Hengrui Medicine Business Model Canvas, not a mockup. When you purchase, you’ll receive this exact file—complete, formatted and ready to edit. No placeholders, no surprises; the full deliverable is provided as shown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D talent pool\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMultidisciplinary scientists across chemistry, biology and clinical specialties form Hengrui’s core R\u0026amp;D bench, supporting a pipeline that benefited from RMB 8.1 billion in R\u0026amp;D spend in 2023. Experienced trial operations and biostatistics teams manage hundreds of domestic and international studies, while medical affairs generates and communicates evidence across payor and KOL channels. Leadership includes executives with prior FDA and EMA regulatory experience, enabling coordinated global submissions and lifecycle strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual property\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui protects core assets with patents covering small-molecule compounds, formulations and biologics processes, supported by a 2024 portfolio of over 1,000 granted patents. Data exclusivity and trade secrets complement patents to sustain pricing power and market share in China and export markets. Routine freedom-to-operate analyses limit litigation and clearance delays, while targeted out-licensing of non-core IP generates milestone and royalty revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine maintains multiple GMP-certified facilities for both small-molecule and biologic production. Sterile injectable lines and dedicated QC laboratories support batch reliability and regulatory compliance. Capacity is structured to serve large domestic demand and growing export markets, while digitalized manufacturing and MES\/ERP traceability systems enhance yield and batch tracking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical \u0026amp; real-world data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical trial datasets, national registries and post‑marketing safety databases underpin Hengrui's value stories; WHO VigiBase exceeded 30 million ICSRs by 2024, supporting signal detection. Analytics platforms enable patient segmentation and actionable insights. RWE increasingly supports label expansions and payer negotiations while strict data governance preserves integrity and regulatory compliance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrial datasets: controlled RCT evidence\u003c\/li\u003e\n\u003cli\u003eRegistries: long‑term outcomes\u003c\/li\u003e\n\u003cli\u003ePost‑marketing safety: VigiBase \u0026gt;30M (2024)\u003c\/li\u003e\n\u003cli\u003eAnalytics platforms: segmentation \u0026amp; predictive models\u003c\/li\u003e\n\u003cli\u003eRWE: label expansion \u0026amp; payer evidence\u003c\/li\u003e\n\u003cli\u003eData governance: integrity \u0026amp; compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand \u0026amp; relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJiangsu Hengrui leverages a strong reputation for quality and innovation in China’s hospital market, with flagship oncology and surgical portfolios widely adopted. Deep ties with KOLs and leading centers accelerate clinical adoption and guideline inclusion. Robust distributor, procurement and tender relationships ensure consistent hospital access, while a respected employer brand attracts top scientific talent.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReputation: trusted in hospital procurement\u003c\/li\u003e\n\u003cli\u003eKOLs: drive guideline adoption\u003c\/li\u003e\n\u003cli\u003eDistribution: secured tender access\u003c\/li\u003e\n\u003cli\u003eTalent: attracts leading researchers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D powerhouse: \u003cstrong\u003eRMB 8.1B\u003c\/strong\u003e spend, \u003cstrong\u003e1,000+\u003c\/strong\u003e patents, global safety data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMultidisciplinary R\u0026amp;D team supported RMB 8.1 billion R\u0026amp;D spend in 2023 and global regulatory experience. Patent portfolio \u0026gt;1,000 grants (2024) plus data exclusivity and trade secrets. Multiple GMP-certified sites with sterile injectable capacity and MES\/ERP. Rich clinical datasets (VigiBase \u0026gt;30M ICSRs 2024) and strong hospital\/KOL channels.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 8.1B (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,000 grants (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety data\u003c\/td\u003e\n\u003ctd\u003eVigiBase \u0026gt;30M ICSRs (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacilities\u003c\/td\u003e\n\u003ctd\u003eMultiple GMP sites; sterile injectable lines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBreakthrough oncology options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovative oncology portfolio addresses high unmet needs with measurable outcomes, supported by 30+ registered oncology trials as of 2024; precision biomarker strategies aim to lift response rates versus historical controls, while pivotal studies report robust tolerability with grade 3–4 adverse event rates generally ≤15%; ongoing Phase II\/III programs target earlier-line approvals and market expansion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardio-metabolic efficacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTreatments target highly prevalent cardio-metabolic conditions—cardiovascular disease causes 17.9 million deaths yearly (WHO) and 537 million adults live with diabetes (IDF 2021). Evidence-backed risk reduction from outcome studies strengthens formulary uptake among clinicians and payers. Once-daily, convenient dosing supports real-world adherence. Competitive pricing enables broader access across China and emerging markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh quality at accessible cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrong manufacturing scale and integrated facilities drive cost efficiency at Jiangsu Hengrui, supporting value pricing that expanded patient reach; in 2024 the company reported revenue of RMB 44.5 billion, with GMP-compliant plants and ISO systems meeting global standards to ensure trust. Reliable supply chains and high production uptime minimize therapy interruptions, reinforcing affordable access to high-quality medicines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal regulatory-grade data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTrials are prospectively designed to meet NMPA, FDA and EMA endpoints, supporting multi-jurisdiction filings and accelerating global uptake; Jiangsu Hengrui reported ~RMB 43.1 billion revenue in 2023, underwriting expanded global trials in 2024.\u003c\/p\u003e\n\u003cp\u003ePeer-reviewed publications and congress data build credibility with KOLs and payers; companion diagnostics increase differentiation and label precision.\u003c\/p\u003e\n\u003cp\u003eRobust post-marketing commitments and real-world evidence programs sustain long-term value and reimbursement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory-aligned trials: NMPA \/ FDA \/ EMA\u003c\/li\u003e\n\u003cli\u003ePublications: KOL + congress visibility\u003c\/li\u003e\n\u003cli\u003eCompanion diagnostics: precision differentiation\u003c\/li\u003e\n\u003cli\u003ePost-marketing RWE: lifecycle value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad, resilient portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpbroad resilient portfolio across oncology cardiometabolic and immunology reduces single-asset risk lifecycle management extensions biologics sustains revenue durability while combination strategies with in-house pd-1 novel agents unlock clinical commercial synergies pipeline continuity clinical-stage programs by long-term growth.\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ediversified therapeutic coverage\u003c\/li\u003e\n\u003cli\u003elifecycle-driven revenue stability\u003c\/li\u003e\n\u003cli\u003ecombination synergies\u003c\/li\u003e\n\u003cli\u003epipeline continuity: 200+ programs (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pbroad\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRMB 44.5B scale fuels 200+ clinical programs and 30+ oncology trials with precision RWE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntegrated value proposition: scalable manufacturing and RMB 44.5 billion 2024 revenue enable affordable pricing and reliable supply; 200+ clinical programs (2024) and 30+ registered oncology trials deliver pipeline continuity and earlier-line expansion; precision biomarker strategies, companion diagnostics and robust RWE drive payer\/KOL uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eRMB 44.5 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical programs\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology trials\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey account management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated key-account teams, as of 2024 covering about 1,200 major hospitals and procurement groups, manage tailored supply, formulary access, and clinician training for Jiangsu Hengrui Medicine. Joint planning sessions align production schedules and formulary placement to demand forecasts, reducing stockouts and excess inventory. Service levels are monitored against clear SLAs with KPIs, and defined escalation paths resolve critical issues within 24–72 hours.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical liaison support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMSLs at Jiangsu Hengrui deliver scientific exchanges and respond to HCP inquiries, supporting clinical uptake and safety monitoring. Advisory boards and CMEs—used in dozens of programs annually—foster peer learning and guideline-aligned practice. Field insights from MSLs feed evidence-generation priorities; Hengrui reported R\u0026amp;D investment over 10% of revenue in 2023 to support that pipeline. All activities follow ethical, non-promotional standards and China\/EU industry codes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient support programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatient support programs deliver access assistance, education, and digital adherence tools that improve outcomes; WHO estimates adherence to long-term therapies averages about 50% in developed settings. Financial support and co-pay assistance reduce treatment abandonment and lower out-of-pocket barriers. Dedicated pharmacovigilance channels feed real-world safety data into registries. Continuous patient feedback loops refine service design and targeting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital engagement combines omnichannel touchpoints—webinars, HCP portals and e-detailing—with tailored content matching prescriber preferences; data-driven nudges raised digital conversion in pharma pilots by over 20% in 2024, improving retention while secure platforms align with China’s Personal Information Protection Law to safeguard patient and HCP data.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOmnichannel: webinars, portals, e-detailing\u003c\/li\u003e\n\u003cli\u003ePersonalization: content by HCP preference\u003c\/li\u003e\n\u003cli\u003eData nudges: +20% conversion (2024 pilots)\u003c\/li\u003e\n\u003cli\u003eCompliance: PIPL-aligned security\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-market safety \u0026amp; quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs of 2024 Jiangsu Hengrui maintains 24\/7 adverse event reporting to meet NMPA and ICH requirements, ensuring regulatory compliance and rapid signal detection. Product quality hotlines deliver fast resolution and escalation to CAPA, while periodic safety updates and PSUR-style reporting keep clinicians and regulators informed.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 adverse event reporting\u003c\/li\u003e\n\u003cli\u003eProduct quality hotlines for rapid resolution\u003c\/li\u003e\n\u003cli\u003ePeriodic safety updates to stakeholders\u003c\/li\u003e\n\u003cli\u003eCAPA-driven continuous improvement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey-account teams cover \u003cstrong\u003e~1,200\u003c\/strong\u003e hospitals; digital pilots \u003cstrong\u003e+20%\u003c\/strong\u003e conversion; R\u0026amp;D \u003cstrong\u003e\u0026gt;10%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDedicated key-account teams cover ~1,200 major hospitals (2024), aligning supply and formularies; MSLs and advisory boards drive clinical uptake while R\u0026amp;D \u0026gt;10% revenue (2023) informs evidence generation. Omnichannel digital nudges delivered +20% conversion in 2024 pilots; 24\/7 adverse-event reporting meets NMPA\/ICH SLAs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/Latest\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey hospitals\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10% revenue (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital conversion\u003c\/td\u003e\n\u003ctd\u003e+20% (2024 pilots)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAE reporting\u003c\/td\u003e\n\u003ctd\u003e24\/7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital tendering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProvincial and national tenders secure formulary placement across tertiary hospitals, driving volume access. Robust value dossiers and pharmacoeconomic models underpin competitive bids, demonstrating cost-effectiveness versus alternatives. Compliance with China’s volume-based procurement frameworks mitigates price and supply risks—centralized pilots cut average drug prices by about 52%. Dedicated post-award service teams sustain contract performance and hospital relationships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributor networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational and regional distributors extend Jiangsu Hengrui Medicine reach to clinics and pharmacies across 31 provincial-level jurisdictions in China. Cold-chain logistics maintain biologics at 2–8°C (or frozen when required) to protect potency. Shared inventory visibility across distributor portals reduces waste and expiries. Performance incentives tie distributor pay to sell-through KPIs, commonly measured as monthly sell-through rate targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect sales to key centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect sales to key centers provide strategic accounts (hospital leaders and KOLs) with dedicated coverage for control and insight, aligned with Jiangsu Hengrui Medicine (Shanghai Stock Exchange: 600276). Specialized reps manage complex therapies and follow administration protocols. Ongoing training and in-servicing drive adoption. Captured CRM and patient-use data inform forecasting and inventory allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital HCP platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpdigital hcp platforms e-detailing tele-reps and medical portals deliver targeted content efficiently with surveys showing about of hcps in china favoring digital engagement webinars virtual congress booths scale education to thousands per event crm consolidates interactions across channels compliance guardrails ensure regulatory rigor.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eE-detailing\/tele-reps: efficient reach; 65% HCP digital preference (2024)\u003c\/li\u003e\n\u003cli\u003eWebinars\/virtual booths: scale to thousands of attendees\u003c\/li\u003e\n\u003cli\u003eCRM: unified interaction records across channels\u003c\/li\u003e\n\u003cli\u003eCompliance: mandatory audit trails and SOP enforcement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdigital\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInternational partners: local licensees and distributors extend Jiangsu Hengrui Medicine into overseas markets, leveraging 2024 regulatory and cultural expertise to accelerate product uptake; strict supply and quality terms safeguard brand integrity while joint marketing programs amplify commercial reach.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket expansion: local licensees\u003c\/li\u003e\n\u003cli\u003eRegulatory edge: 2024 compliance support\u003c\/li\u003e\n\u003cli\u003eQuality: supply terms protect brand\u003c\/li\u003e\n\u003cli\u003eGrowth: joint marketing amplifies reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTenders cut prices \u003cstrong\u003e~52%\u003c\/strong\u003e; digital HCP reach \u003cstrong\u003e65%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProvincial\/national tenders secure hospital formulary access; centralized pilots cut avg drug prices ~52% (2024). Distributors cover 31 provinces with cold-chain for biologics (2–8°C); sell-through KPIs drive incentives. Direct sales target key hospitals; CRM and patient-use data inform supply. Digital channels favored by ~65% HCPs (2024), supporting webinars and e-detailing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTenders\u003c\/td\u003e\n\u003ctd\u003ePrice cut ~52%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003e31 provinces\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital HCP\u003c\/td\u003e\n\u003ctd\u003e65% prefer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTertiary hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTertiary hospitals, about 3,000 in China, are high-volume oncology and complex-care centers that drive early adoption of Hengrui therapies; they handle over 60% of complex oncology cases nationally. Multidisciplinary teams demand robust RCT and real-world evidence and purchasing committees prioritize clear cost-effectiveness and HTA submissions. Rollouts require significant training investments, typically 20–40 clinician-hours per new therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncologists, cardiologists and endocrinologists are primary prescribers of Jiangsu Hengrui medicines, driving uptake across oncology and specialty portfolios; Hengrui reported ~RMB 54.2 billion revenue in 2023 with heavy specialty focus. KOLs materially shape national guidelines and peer prescribing behavior, amplifying adoption. Robust clinical evidence and safety data determine formulary placement, while dosing convenience and delivery influence patient adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment \u0026amp; payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNational and provincial payers set reimbursement and tender access that determine volumes and pricing for Jiangsu Hengrui, with centralized procurement historically achieving price cuts up to 70%. HTA bodies assess value and budget impact, shaping NRDL inclusion and hospital adoption. Policy shifts in 2024 accelerated tender consolidation, influencing \u0026gt;95% of public hospital drug purchasing. Real-world outcomes and registry data now directly affect reimbursement renewals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail \u0026amp; specialty pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRetail and specialty pharmacies extend Jiangsu Hengrui Medicine distribution beyond hospitals for chronic and specialty therapies, where inventory levels and patient counseling materially influence adherence and outcomes. Close collaboration with pharmacies enhances timely access and refill rates through integrated support programs. Structured data sharing on dispensing and patient demand enables more accurate forecasting and supply planning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannel: outpatient access for chronic\/specialty meds\u003c\/li\u003e\n\u003cli\u003eAdherence: inventory + counseling affect persistence\u003c\/li\u003e\n\u003cli\u003eCollaboration: improves access and refill frequency\u003c\/li\u003e\n\u003cli\u003eData: dispensing data informs demand planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEx-China customers reached via partners and overseas subsidiaries drive incremental revenue, with international sales representing about 10% of Hengrui’s 2024 revenues as the company scales oncology and biologics exports.\u003c\/p\u003e\n\u003cp\u003eApproval timelines and pricing diverge by region (FDA 6–10 months priority\/standard, EMA centralized 210 days excluding clock stops), local HTA and guideline differences shape adoption, and pharmacovigilance obligations (global serious AE reporting within 15 days) extend compliance costs and risk management.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eInternational sales ~10% of 2024 revenue\u003c\/li\u003e\n\u003cli\u003eFDA review 6–10 months; EMA 210 days\u003c\/li\u003e\n\u003cli\u003eLocal HTA\/guidelines drive uptake\u003c\/li\u003e\n\u003cli\u003eGlobal PV: serious AE reporting within 15 days\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTertiary hospitals (~3,000) drive adoption: \u0026gt;60% oncology; 20-40h training; tenders force 70% cuts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTertiary hospitals (~3,000) drive early adoption (\u0026gt;60% complex oncology) and require 20–40 clinician-hours training. Prescribers (oncology, cardio, endocrinology) and KOLs dictate formulary placement; Hengrui reported RMB 54.2bn revenue in 2023 and international sales ~10% of 2024 revenue. Payers\/tenders (\u0026gt;95% public procurement) force price cuts up to 70% and HTA-driven access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTertiary hospitals\u003c\/td\u003e\n\u003ctd\u003e~3,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComplex oncology share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining\u003c\/td\u003e\n\u003ctd\u003e20–40 clinician-hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 54.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl sales (2024)\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic procurement\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMax tender cut\u003c\/td\u003e\n\u003ctd\u003eUp to 70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiscovery, preclinical and multi-phase trials are the largest cost drivers for Jiangsu Hengrui, with R\u0026amp;D spend rising from about RMB 12.7 billion in 2023 to a 2024 target near RMB 15 billion; external CRO fees scale with pipeline breadth and can represent 10–20% of trial budgets. Site fees, monitoring and data management add substantial per-trial overheads, while biomarker and companion diagnostic development raises complexity and incremental costs by millions per study.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing \u0026amp; COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRaw materials, biologics inputs and sterile operations are the primary cost drivers for Jiangsu Hengrui, with ongoing validation, QA\/QC and regulatory compliance creating continuous overhead. Yield improvements from process optimization and scale-up directly lower unit COGS, while higher energy and utilities consumption erodes margins and must be managed through efficiency investments. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulatory and market-access activities consume significant resources: submission preparation, fees and inspections drive personnel and external consultancy costs; Hengrui reported RMB 8.14 billion R\u0026amp;D spend in 2023, with regulatory\/MA a material share. HEOR, HTA and pricing dossiers add ongoing expense and typically account for 10–20% of launch budgets. Post-marketing commitments and localization of dossiers for over 50 markets sustain recurring spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, marketing, medical\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eField forces, MSLs, congresses and digital channels require sustained funding for deployment, ongoing training and content development, while CRM and analytics platforms create recurring IT and data-overhead; educational grants and investigator-initiated studies fund evidence generation and KOL engagement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField forces \u0026amp; MSLs: staffing and training costs\u003c\/li\u003e\n\u003cli\u003eCongresses \u0026amp; digital: event + omni-channel spend\u003c\/li\u003e\n\u003cli\u003eCRM\/analytics: platform OPEX\u003c\/li\u003e\n\u003cli\u003eGrants\/studies: evidence-building spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapex \u0026amp; overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCapex for plant expansions, equipment upgrades and IT systems requires significant upfront funding, while ongoing facility maintenance and depreciation create steady overhead; Jiangsu Hengrui sustains these costs alongside heavy R\u0026amp;D-driven operations. Talent acquisition and retention push HR expenses higher, particularly for clinical, manufacturing and regulatory specialists. Compliance and legal costs remain material due to global trials and export markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapex: plant, equipment, IT\u003c\/li\u003e\n\u003cli\u003eOngoing: maintenance, depreciation\u003c\/li\u003e\n\u003cli\u003eHR: hiring, retention for specialized staff\u003c\/li\u003e\n\u003cli\u003eCompliance: legal, regulatory across markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D \u003cstrong\u003eRMB~15bn\u003c\/strong\u003e; CRO fees \u0026amp; manufacturing drive recurring launch costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiscovery, preclinical and trials drive costs; R\u0026amp;D rose from about RMB 12.7bn in 2023 to a 2024 target near RMB 15bn, with CRO fees ~10–20% of trial budgets. Manufacturing (raw materials, biologics, sterile ops) and QA\/QC create ongoing COGS pressure while capex and depreciation sustain fixed overheads. Commercial, regulatory\/MA and HEOR\/HTA (10–20% of launch budgets) add recurring spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2023\u003c\/td\u003e\n\u003ctd\u003eRMB 12.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2024 target\u003c\/td\u003e\n\u003ctd\u003eRMB ~15bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO fees\u003c\/td\u003e\n\u003ctd\u003e10–20% of trial budget\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReg\/MA launch\u003c\/td\u003e\n\u003ctd\u003e10–20% of launch budget\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDomestic drug sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDomestic drug sales remain the core revenue engine for Jiangsu Hengrui, accounting for about 78% of group revenue in 2024 with primary distribution through hospital and pharmacy channels. Oncology and chronic disease portfolios continue to lead contribution, with novel oncology launches driving volume and ASP mix. National volume-based procurement in 2024 compressed prices for selected generics, but Hengrui’s brand strength preserved market share and premium positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExports and licensed products generate foreign revenue, contributing roughly 10–15% of Jiangsu Hengrui Medicine’s sales (2023 revenue ~RMB 60bn). Regional pricing and access compress margins in emerging markets versus Europe\/US. Growing approvals in 2023–24 expanded footprints to 30+ markets. Currency swings (RMB vs USD\/EUR moved ~5–8% in 2023–24) add variability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing \u0026amp; royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOut-licensing by Jiangsu Hengrui yields upfronts, milestone payments and tiered royalties—upfronts often range from tens to hundreds of millions USD while royalties commonly fall between 5–20%. Co-development deals typically split R\u0026amp;D costs and upside (eg. ~50\/50), sharing risk. IP monetization via sublicenses and territory rights extends revenue beyond direct sales. Milestone timing (often 3–7 years) materially affects cash flow timing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-promotion services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-promotion partnerships expand Jiangsu Hengrui Medicine’s income by adding complementary therapies alongside its proprietary portfolio; after reporting RMB 46.9 billion revenue in 2023, Hengrui scaled such alliances into 2024 to broaden market access.\u003c\/p\u003e\n\u003cp\u003eShared field resources from co-promotions raise commercial efficiency and lower incremental sales cost, performance-based fee structures align partner incentives with uptake, and cross-detailing increases portfolio breadth and physician reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartnerships: add complementary therapies, expand market access\u003c\/li\u003e\n\u003cli\u003eShared resources: improve field efficiency, reduce incremental costs\u003c\/li\u003e\n\u003cli\u003ePerformance fees: align commercial incentives with sales\u003c\/li\u003e\n\u003cli\u003eCross-detailing: supports broader portfolio coverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLinked companion diagnostics drive targeted therapy uptake—global companion diagnostics market reached an estimated $4.2 billion in 2024, supporting Hengrui’s targeted oncology launches and higher prescription conversion rates.\u003c\/p\u003e\n\u003cp\u003eBundled test-plus-drug or partnered-lab models create ancillary revenue streams and margin protection; Hengrui can capture service fees and share NSCLC\/CRC testing margins with partners.\u003c\/p\u003e\n\u003cp\u003eReal-world testing data strengthen outcomes claims for label expansion and HEOR dossiers; payer reimbursement policies, with varied provincial coverage in China, remain the primary determinant of adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003emarket-size-2024:$4.2B\u003c\/li\u003e\n\u003cli\u003erevenue-ancillaries:service-fees\/shared-margins\u003c\/li\u003e\n\u003cli\u003eevidence:real-world-data→HEOR\/label-expansion\u003c\/li\u003e\n\u003cli\u003eaccess-driver:reimbursement\/geographic-coverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDomestic drugs: \u003cstrong\u003e78%\u003c\/strong\u003e of revenue; 2023 sales \u003cstrong\u003eRMB 46.9bn\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDomestic drug sales were the core engine, ~78% of group revenue in 2024, led by oncology and chronic portfolios via hospital\/pharmacy channels.\u003c\/p\u003e\n\u003cp\u003eExports and licensing contributed ~10–15% of sales; out‑licensing upfronts often tens–hundreds MUSD, royalties typically 5–20% with 3–7 year milestone timing.\u003c\/p\u003e\n\u003cp\u003eCo‑promotions, bundled test‑plus‑drug models and companion diagnostics (global market $4.2B in 2024) provide ancillaries; 2023 revenue RMB 46.9bn.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 46.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 domestic share\u003c\/td\u003e\n\u003ctd\u003e~78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports\/licensing\u003c\/td\u003e\n\u003ctd\u003e~10–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e5–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompanion Dx market 2024\u003c\/td\u003e\n\u003ctd\u003e$4.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097913561436,"sku":"henrui-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/henrui-business-model-canvas.png?v=1781796467","url":"https:\/\/pestel-analysis.com\/products\/henrui-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}